Jill Feldman: We must talk about pneumonitis in lung cancer
Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:
“We must talk about pneumonitis in lung cancer treatment!
Resistance is horrible, but you understand the reasoning behind stopping treatment. When a treatment is working and has to be stopped due to pneumonitis, it sidelines patients & eliminates many future options – It is cruel and DEVASTATING!
This needs more attention, more research, and urgency to:
- Understand who’s at risk?
- Improve how it is managed.
- Identify treatment options.”
Eric K. Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, reshared the post on X, adding:
“GREAT points as always, Jill Feldman.
Immunotherapy, targeted therapy, ADCs and radiation can all potentially lead to pneumonitis—and many promising trials exclude patients with a history of it.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023